<code id='F6DD64A25E'></code><style id='F6DD64A25E'></style>
    • <acronym id='F6DD64A25E'></acronym>
      <center id='F6DD64A25E'><center id='F6DD64A25E'><tfoot id='F6DD64A25E'></tfoot></center><abbr id='F6DD64A25E'><dir id='F6DD64A25E'><tfoot id='F6DD64A25E'></tfoot><noframes id='F6DD64A25E'>

    • <optgroup id='F6DD64A25E'><strike id='F6DD64A25E'><sup id='F6DD64A25E'></sup></strike><code id='F6DD64A25E'></code></optgroup>
        1. <b id='F6DD64A25E'><label id='F6DD64A25E'><select id='F6DD64A25E'><dt id='F6DD64A25E'><span id='F6DD64A25E'></span></dt></select></label></b><u id='F6DD64A25E'></u>
          <i id='F6DD64A25E'><strike id='F6DD64A25E'><tt id='F6DD64A25E'><pre id='F6DD64A25E'></pre></tt></strike></i>

          fashion

          fashion

          author:fashion    Page View:81692
          Bristol Myers Squibb sign
          Courtesy Bristol Myers Squibb

          Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

          RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

          advertisement

          Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          PBM reforms clear House panel
          PBM reforms clear House panel

          SarahSilbiger/GettyImagesWASHINGTON—PanelsinboththeHouseandSenatehavenowpassedrestrictionstodrugmidd

          read more
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more

          Reports of telehealth's death have been greatly exaggerated

          Adobe“Telehealthiscollapsing.”“Telehealthisgoingthroughacontraction.”“Thereisadarkcloudhoveringoverv